^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Source:
Title:

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

Excerpt:
Within 1 week after the start of crizotinib treatment, his symptoms improved markedly...Although he had a partial response to the treatment, his pleural effusion was not completely eradicated (Figure 1 in the Supplementary Appendix)...After 5 months of treatment, however, the tumor abruptly started to grow again, resulting in a rapid expansion of the pleural effusion and in the development of tumors in both lungs (Figure 1 in the Supplementary Appendix).
DOI:
10.1056/NEJMoa1007478
Trial ID: